

---

## Overview

**Useful For**

Evaluation of Rac2 deficiency and *RAC2* gain of function

**Method Name**

Flow Cytometry

**NY State Available**

Yes

## Specimen

**Specimen Type**

WB Sodium Heparin

**Shipping Instructions**

Testing performed Monday through Friday. **Specimens not received by 4 p.m. Central time on Fridays may be canceled.**

Collect and package specimen as close to shipping time as possible. Ship specimen overnight in an Ambient Shipping Box-Critical Specimens Only (T668) following the instructions in the mailer. It is recommended that specimens arrive within 24 hours of collection.

Specimens arriving on the weekend and observed holidays may be canceled.

**Necessary Information**

**Ordering healthcare professional name and phone number are required.**

**Specimen Required**

**Two whole-blood sodium heparin specimens are required, one from the testing patient and the other from an unrelated healthy donor as a control.**

**Supplies:** Ambient Shipping Box-Critical Specimens Only (T668)

**Patient:**

**Container/Tube:** Green top (sodium heparin)

**Specimen Volume:** 5 mL

**Collection Instructions:** Send whole blood specimen in original tube. **Do not aliquot.**

**Normal Control:**

**Container/Tube:** Green top (sodium heparin)

**Specimen Volume:** 5 mL

**Collection Instructions:**

1. Collect a control specimen from the unrelated healthy donor within an hour of the patient's specimen collection time.
2. Clearly label as **Normal Control** on the outermost label.
3. Send the whole blood specimen in the original tube. **Do not aliquot.**
4. **Rubber band patient specimen and control vial together.**

**Specimen Minimum Volume**

1 mL

**Reject Due To**

Gross hemolysis	Reject
Gross lipemia	Reject

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
WB Sodium Heparin	Ambient	48 hours	GREEN TOP/HEP

**Clinical & Interpretive**

**Clinical Information**

This assay can be used for the diagnostic evaluation of Rac2 deficiency, which is a neutrophil defect that causes profound neutrophil dysfunction with decreased chemotaxis, polarization, superoxide anion production, azurophilic granule secretion. This disease is caused by inhibitory variants in the *RAC2* gene, which encodes a Rho family GTPase essential to neutrophil activation and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) function.(1) Patients with Rac2 deficiency have been shown to have normal neutrophil oxidative burst when stimulated with phorbol myristate acetate (PMA), indicating normal NOX activity but abnormal neutrophil responses to N-formyl-methionyl-leucyl-phenylalanine (fMLP), which is a physiological activator of neutrophils. The defective oxidative burst to fMLP, but not to PMA, is consistent with Rac2 deficiency.(2) By contrast, gain of function variants in *RAC2* would lead to an exaggerated response to fMLP.(3)

**Reference Values**

Result name	Unit	Cutoff for defining normal
% fMLP ox-DHR+	%	> or =10%
MFI fMLP ox-DHR+	MFI	> or =2

## Test Definition: DHRF

Dihydrorhodamine Flow Cytometric  
N-Formyl-Methionyl-Leucyl-Phenylalanine  
Test, Blood

Control % fMLP ox-DHR+	%	> or =10%
Control MFI fMLP ox-DHR+	MFI	> or =2

fMLP = N-formyl-methionyl-leucyl-phenylalanine

DHR = dihydrorhodamine

MFI = mean fluorescence intensity

The appropriate age-related reference values for Absolute Neutrophil Count will be provided on the report.

### Interpretation

An interpretive report will be provided, in addition to the quantitative values described in Clinical Information.

Interpretation of the results of the quantitative dihydrorhodamine (DHR) flow cytometric assay must include both the proportion of positive neutrophils for DHR after N-formyl-methionyl-leucyl-phenylalanine stimulation and the mean fluorescence intensity.

### Cautions

Specimens are optimally tested within 24 hours of blood draw, though the stability of the assay is within 48 hours of collection. Specimens should be collected in sodium heparin and transported under strict ambient conditions. Use of the Ambient Mailer-Critical Specimens Only box (T668) is encouraged to ensure appropriate transportation of the specimen.

Hemolyzed specimens may interfere with the assay (ie, high background).

Specimens with an absolute neutrophil count below 200 will not be accepted for this assay. Complete myeloperoxidase deficiency can yield a false-positive result.

### Supportive Data

Dihydrorhodamine analysis was performed to assess neutrophil oxidative burst in 157 healthy donors, 74 children, and 83 adults.

### Clinical Reference

1. Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. *Proc Natl Acad Sci U S A*. 2000;97(9):4654-4659
2. Accetta D, Syverson G, Bonacci B, et al. Human phagocyte defect caused by a RAC2 mutation detected by means of neonatal screening for T cell lymphopenia. *J Allergy Clin Immunol*. 2011;127(2):535-538
3. Hsu AP, Donko A, Arrington ME, et al. Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects. *Blood*. 2019;133(18):1977-1988

### Performance

### Method Description

---

A sodium heparin whole blood specimen is incubated at 37 degrees C in the presence of DHR123. N-formyl-methionyl-leucyl-phenylalanine (fMLP) stimulant is added and mixed with the whole blood specimen for additional incubation at 37 degrees C. The sample is then centrifuged, and cell pellet is subsequently lysed with ammonium chloride at room temperature. Lysed samples are then washed with azide-free phosphate buffered saline prior to staining with LIVE/DEAD viability marker and CD15 at ambient temperature. Finally, cells are washed, centrifuged, and resuspended in 1% paraformaldehyde prior to analysis. Viable neutrophils are identified by the use of the viability dye and further confirmed by the presence of CD15. Approximately 20,000 viable neutrophil events in the unstimulated sample are used to set the limits for number of events collected for flow cytometry. The results are derived as delta % DHR+ neutrophils after fMLP stimulation and mean fluorescence intensity. (O'Gorman MR, Corrochano V. Rapid whole-blood flow cytometry assay for diagnosis of chronic granulomatous disease. Clin Diagn Lab Immunol. 1995;2[2]:227-232; Kuhns DB. Diagnostic testing for chronic granulomatous disease. Methods Mol Biol. 2019;1982:543-571)

**PDF Report**

No

**Day(s) Performed**

Monday through Friday

**Report Available**

3 to 4 days

**Specimen Retention Time**

4 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

86352

## Test Definition: DHRF

Dihydrorhodamine Flow Cytometric  
N-Formyl-Methionyl-Leucyl-Phenylalanine  
Test, Blood

---

### LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
DHRF	DHR Flow fMLP, B	98123-3

Result ID	Test Result Name	Result LOINC® Value
ANC	Absolute Neutrophil Count	751-8
FMPPP	% fMLP ox-DHR+	85373-9
FMPM	MFI fMLP ox-DHR+	85370-5
ANCC	Control Absolute Neutrophil Count	85369-7
FMPPC	Control % fMLP ox-DHR+	85372-1
FMPMC	Control MFI fMLP ox-DHR+	85371-3
DHRFI	Interpretation	69052-9